TY - JOUR
T1 - Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer
T2 - Response to Met inhibition in patient xenografts and pathologic correlations
AU - Galimi, Francesco
AU - Torti, Davide
AU - Sassi, Francesco
AU - Isella, Claudio
AU - Corà, Davide
AU - Gastaldi, Stefania
AU - Ribero, Dario
AU - Muratore, Andrea
AU - Massucco, Paolo
AU - Siatis, Dimitrios
AU - Paraluppi, Gianluca
AU - Gonella, Federica
AU - Maione, Francesca
AU - Pisacane, Alberto
AU - David, Ezio
AU - Torchio, Bruno
AU - Risio, Mauro
AU - Salizzoni, Mauro
AU - Capussotti, Lorenzo
AU - Perera, Timothy
AU - Medico, Enzo
AU - Di Renzo, Maria Flavia
AU - Comoglio, Paolo M.
AU - Trusolino, Livio
AU - Bertotti, Andrea
PY - 2011/5/15
Y1 - 2011/5/15
N2 - Purpose: We determined the gene copy numbers for MET, for its transcriptional activator MACC1 and for its ligand hepatocyte growth factor (HGF) in liver metastases from colorectal carcinoma (mCRC). We correlated copy numbers with mRNA levels and explored whether gain and/or overexpression of MET and MACC1 predict response to anti-Met therapies. Finally, we assessed whether their genomic or transcriptional deregulation correlates with pathologic and molecular parameters of aggressive disease. Experimental Design: One hundred three mCRCs were analyzed. Copy numbers and mRNA were determined by quantitative PCR (qPCR). Thirty nine samples were implanted and expanded in NOD (nonobese diabetic)/SCID (severe combined immunodeficient) mice to generate cohorts that were treated with the Met inhibitor JNJ-38877605. In silico analysis of MACC1 targets relied on genome-wide mapping of promoter regions and on expression data from two CRC datasets. Results: No focal, high-grade amplifications of MET, MACC1, or HGF were detected. Chromosome 7 polysomy and gain of the p-arm were observed in 21% and 8% of cases, respectively, and significantly correlated with higher expression of both Met and MACC1. Met inhibition in patient-derived xenografts did not modify tumor growth. Copy number gain and overexpression of MACC1 correlated with unfavorable pathologic features better than overexpression of Met. Bioinformatic analysis of putative MACC1 targets identified elements besides Met, whose overexpression cosegregated with aggressive forms of colorectal cancer. Conclusions: Experiments in patient-derived xenografts suggest that mCRCs do not rely on Met genomic gain and/or overexpression for growth. On the basis of pathologic correlations and bioinformatic analysis, MACC1 could contribute to CRC progression through mechanisms other than or additional to Met transcriptional upregulation.
AB - Purpose: We determined the gene copy numbers for MET, for its transcriptional activator MACC1 and for its ligand hepatocyte growth factor (HGF) in liver metastases from colorectal carcinoma (mCRC). We correlated copy numbers with mRNA levels and explored whether gain and/or overexpression of MET and MACC1 predict response to anti-Met therapies. Finally, we assessed whether their genomic or transcriptional deregulation correlates with pathologic and molecular parameters of aggressive disease. Experimental Design: One hundred three mCRCs were analyzed. Copy numbers and mRNA were determined by quantitative PCR (qPCR). Thirty nine samples were implanted and expanded in NOD (nonobese diabetic)/SCID (severe combined immunodeficient) mice to generate cohorts that were treated with the Met inhibitor JNJ-38877605. In silico analysis of MACC1 targets relied on genome-wide mapping of promoter regions and on expression data from two CRC datasets. Results: No focal, high-grade amplifications of MET, MACC1, or HGF were detected. Chromosome 7 polysomy and gain of the p-arm were observed in 21% and 8% of cases, respectively, and significantly correlated with higher expression of both Met and MACC1. Met inhibition in patient-derived xenografts did not modify tumor growth. Copy number gain and overexpression of MACC1 correlated with unfavorable pathologic features better than overexpression of Met. Bioinformatic analysis of putative MACC1 targets identified elements besides Met, whose overexpression cosegregated with aggressive forms of colorectal cancer. Conclusions: Experiments in patient-derived xenografts suggest that mCRCs do not rely on Met genomic gain and/or overexpression for growth. On the basis of pathologic correlations and bioinformatic analysis, MACC1 could contribute to CRC progression through mechanisms other than or additional to Met transcriptional upregulation.
UR - https://www.scopus.com/pages/publications/79956022110
U2 - 10.1158/1078-0432.CCR-10-3377
DO - 10.1158/1078-0432.CCR-10-3377
M3 - Article
SN - 1078-0432
VL - 17
SP - 3146
EP - 3156
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -